Skip to main content
OpenTrials
Completed

NCT Number: NCT03548480

Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment

The gut microbiome has recently emerged as a major contributor to obesity, systemic inflammation, and metabolic disease. Furthermore, intestinal bacteria are crucial players in the gut-brain axis, regulating a broad range of central nervous system processes, from satiety mechanisms to anxiety and social behavior. Thus, targeting the microbiome is being actively investigated as a therapeutic strategy for a wide array of diseases, including obesity, anxiety, depression, and autism. Among all intestinal bacteria, Bifidobacterium animalis spp. lactis (BAL) has shown promise for obesity treatment in experimental animal models and human subjects, improving body composition and metabolic health, and reducing energy intake. Moreover, tryptophan metabolism, a crucial regulator of satiety mechanisms and anxiety, is a main target of BAL. Given that clinical manifestations of Prader-Willi syndrome (PWS) include hyperphagia, anxiety, altered body composition, and metabolic dysregulation, the aforementioned effects of BAL might prove highly beneficial for children with PWS. Here, the investigators will test this hypothesis by performing a randomized double-blinded placebo-controlled crossover clinical study to assess the effects of BAL supplementation on an array of clinical manifestations of PWS. Children with PWS will undergo a 3-month placebo/probiotic treatment period, a 3-month washout period, followed by a 3-month probiotic/placebo supplementation. Anthropometric, biochemical, and psychological data as well as biological samples will be obtained at the beginning of the study, and after each of the study periods, with a total of four time-points. Specifically, the investigators will determine body composition by DXA analysis; metabolic health by assessing glucose and lipid metabolic parameters as well as circulating hormonal and cytokine levels; thermoregulation by non-invasive thermal imaging; and hyperphagia and emotional and behavioral problems by applying parental-rated validated questionnaires.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with Prader-Willi Syndrome with genetic confirmation
  • On a stable diet and medication regimen for at least the last two months before enrollment

Exclusion criteria

  • Current enrollment in or discontinuation within the last 30 days from a clinical trial
  • Presence of other medical problems that would preclude study participation
  • Patients with a history of bariatric surgery
  • Unsuitable for inclusion in the study in the opinion of the investigator

Treatment and study plan

Placebo

Dietary Supplement

Intervention with a daily dose of placebo

Probiotic

Dietary Supplement

Intervention with a daily dose of probiotic

Primary outcomes

  1. Change in percent body fat

    Time frame: 3 months

    Measured by DXA scan

Secondary outcomes

  1. Change in lipid profile (triglyceride, cholesterol)

    Time frame: 3 months

    Blood test after overnight fasting

  2. Change in glucose metabolic parameters (glucose, insulin, HbA1c)

    Time frame: 3 months

    Blood test after overnight fasting

  3. Change in circulating cytokine levels

    Time frame: 3 months

    Quantified in plasma samples

  4. Change in hyperphagia

    Time frame: 3 months

    Measured by validated questionnaire (HQ-CT)

  5. Change in thermoregulation

    Time frame: 3 months

    Measured by thermal imaging

Other outcomes

  1. Change in plasma metabolome

    Time frame: 3 months

    Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of plasma samples

  2. Change in urine metabolome

    Time frame: 3 months

    Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of urine samples

  3. Change in intestinal microbiome

    Time frame: 3 months

    DNA isolated from fecal samples will be analyzed by sequencing.

Sponsors and collaborators

Lead sponsor

Fundació Sant Joan de Déu

Other

Registry information

Acronym: BALPWS

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 7, 2018
Registry last updated
Mar 5, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.